Circassia Pharmaceuticals

Circassia Pharmaceuticals adds 'exciting, near-term' respiratory drug to portfolio

Steve Harris, chief executive of Circassia Pharmaceuticals PLC (LON:CIR), tells Proactive London's Andrew Scott they've acquired the exclusive US and Chinese commercialisation rights to AirNOvent – a treatment for persistent pulmonary hypertension (PPHN) of newborns.

PPHN occurs when the pressure in the blood vessels of a baby’s lungs remains high after birth, which can restrict the amount of oxygen flowing around the body and make the newborn unwell.

It's thought to occur in around one in 500 births.

Quick facts: Circassia Pharmaceuticals

Price: £0.19

Market: LSE
Market Cap: £69.78 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Pharmaceuticals named herein, including the promotion by the Company of Circassia Pharmaceuticals in any Content on the Site, the...



Full interview: Leafbuyer Technologies aims to double organic revenue by end...

Leafbuyer Technologies Inc (OTCMKTS:LBUY) CEO Kurt Rossner tells Proactive the Colorado-based cannabis technology platform, which allows dispensaries to advertise on its website, is aiming to double its organic revenues by end of 2019. Rossner explains the company is in a high-growth phase,...

6 hours, 58 minutes ago


Total Voting Rights

3 weeks, 1 day ago

Holding(s) in Company

on 07/22/2019

Holding(s) in Company

on 07/09/2019

Holding(s) in Company

on 07/08/2019

Holding(s) in Company

on 07/05/2019

Holding(s) in Company

on 07/02/2019

Holding(s) in Company

on 07/02/2019

2 min read